Johnson & Johnson, Merck, Bristol-Myers Squibb Upgraded

Johnson & Johnson, Merck, Bristol-Myers Squibb shares are on Jefferies' bullish radar

Mar 9, 2017 at 9:20 AM
facebook X logo linkedin

Analysts are weighing in big-cap drug stocks Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), and Bristol-Myers Squibb Co (NYSE:BMY). Here's a roundup of today's bullish brokerage notes on JNJ, MRK, and BMY shares.

Jefferies Predicts Record Highs for Johnson & Johnson

Jefferies raised its price target on JNJ to $132, representing record-high territory for the Dow stock, and a solid premium to Wednesday's close of $124.10. The shares have been rising in recent weeks, gaining 12% since their late-January low. There's plenty of room for additional bullish attention to come through on Johnson & Johnson, since 11 of 18 covering brokerage firms still rate the equity a "hold" or worse.

Fresh Price-Target Hike for Merck Stock

Jefferies also upped its price target on MRK, setting the bar at $52. However, there's still room to move, considering this new target is at a significant discount to last night's finish at $65.80. Merck & Co., Inc. has had a strong 12 months on the charts, gaining over 25%, and hitting a 15-year high of $66.80 on March 1. In the options pits, though, there's been an unusual uptick in put buying, with the stock's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) coming in at 0.73 -- in the 81st annual percentile. An unwinding of this skepticism could actually help the stock in the near term. 

Jefferies Expects a Bristol-Myers Squibb Bounce

Another drug stock Jefferies weighed in on was BMY, with the brokerage firm setting a price target of $66. This represents 15.6% upside to BMY's Wednesday close at $57.12, and territory not seen since before an August bear gap. Nevertheless, Bristol-Myers Squibb Co shares are trading slightly lower ahead of the bell, on track to add to their roughly 14% year-to-date deficit. Should upbeat analysts begin to change their tune, the stock could see additional technical trouble. Currently, eight of 13 brokerages maintain a "buy" or better rating, leaving the door wide open for downgrades. 

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI